hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
Published 1 year ago • 71 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
1:15
magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
3:40
uronav - targeting higher precision and better outcome in prostate diagnostics
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
12:34
transurethral ultrasound ablation outcomes
-
6:42
low risk (gleason 3 3=6) & intermediate risk (gleason 3 4=7) prostate cancer q a | pcri #13
-
2:16
highly focused radiation treatment offers hope for patients with advanced prostate cancer
-
4:42
biparametric vs multiparametric prostate mri for the detection of pca in treatment‐naïve patients
-
9:23
drs. armstrong, wallis on ai biomarkers and hrqol for localized prostate cancer, mcrpc
-
0:46
new prostate cancer approach from utmb's dr. eric walser
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:59
prostate biopsy: targeted 3-d live in mri - revolutionary method by alta clinic
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
1:54
dr. hahn on patient selection for abiraterone versus docetaxel in mhspc
-
1:06
imaagen: phase 2 trial of abiraterone acetate for advanced prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:34
ocr a level biology a: 5.1.2c - ultrafiltration
-
2:24
multiplex assay for activated p300/cbp in circulating prostate tumor cells | oncotarget
-
1:23
dr. charles ryan abiraterone acetate in elderly mcrpc patients
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer